白细胞减少症
医学
化疗
内科学
不利影响
白细胞
安慰剂
血液学
加药
放射治疗
临床试验
胃肠病学
多中心研究
毒性
治疗效果
多中心试验
外科
肿瘤科
随机对照试验
血球计数
副作用(计算机科学)
外周血
脱发
临床终点
中性粒细胞减少症
血细胞
血液分析仪
阶段(地层学)
作者
Yafang Cai,Peng Xue,Xiaotong Hu,Huijie Wang,Liping Liu,Yi Li,Jun Xiao,Changgang Sun,Yufeng Wang,Shijie Zhu
标识
DOI:10.1016/j.jtcms.2025.11.001
摘要
To assess the efficacy and safety of Qixuekang oral liquid in the treatment of leukopenia during chemotherapy and radiotherapy. This randomized, double-blind, placebo-controlled, multicenter clinical trial was conducted between July 2018 and May 2021. A total of 234 patients with malignant tumors were enrolled from 12 medical centers. They were randomly assigned to receive either Qixuekang oral liquid or placebo in addition to standard chemotherapy and radiotherapy, with a treatment duration ≤ 42 days. The primary outcome was defined as the change in peripheral white blood cell (WBC) count, determined by routine laboratory hematology tests, from baseline (D-7 to D0) to Day 42 (± 2 days) of dosing (D42). In the full analysis set comprising 227 patients (113 and 114 in the experimental and control groups, respectively), a significant reduction in WBC count was observed after treatment ( P < .001). The experimental group exhibited a smaller reduction in WBC count than did the control group ( P = .038). In the per-protocol set ( n = 188), a trend favoring the experimental group was evident, although not statistically significant ( P = .091). No significant differences were observed in the vital signs, laboratory results, or adverse events between the two groups ( P > .05). Qixuekang oral liquid may exert a therapeutic effect in mitigating leukopenia induced by chemotherapy and radiotherapy, while exhibiting favorable safety profiles.
科研通智能强力驱动
Strongly Powered by AbleSci AI